Stanisławska Katarzyna, Stadnik Honorata, Nawrocki Mikołaj, Ramlau-Piątek Katarzyna, Juszkat Robert, Drews Michał
Department of General and Interventional Radiology, Poznan University of Medical Sciences, Poland.
Department of General, Gastroenterological and Endocrinological Surgery, Poznan University of Medical Sciences, Poland.
Contemp Oncol (Pozn). 2017;21(3):244-248. doi: 10.5114/wo.2017.70115. Epub 2017 Sep 29.
Treatment of unresectable liver metastases (LM) from uveal melanoma (UM) remains a major clinical challenge. Systemic chemotherapy and chemoimmunotherapy regimens extrapolated from cutaneous melanoma are considered to be ineffective in therapy of metastases from uveal melanoma. Studies suggest that the progression of hepatic metastases rather than the primary tumor or metastases in other organs determines survival.
We report a case of transarterial chemoembolization of 57-year-old man diagnosed with unresectable liver metastases from uveal melanoma with irinotecan eluting beads. Therapy resulted in long progression free survival and overall survival, 41 months and 45 months after diagnosis of metastatic disease respectively. Patient did not experience any major side effects of the therapy. Follow-up CTs indicate stable disease in mRECIST criteria and partial response in CHOI criteria.
Transarterial chemoembolization with drug eluting beads loaded with irinotecan may be an effective treatment of unresectable liver metastases from uveal melanoma.
葡萄膜黑色素瘤（UM）不可切除肝转移灶（LM）的治疗仍然是一项重大临床挑战。从皮肤黑色素瘤推断而来的全身化疗和化学免疫治疗方案在葡萄膜黑色素瘤转移灶的治疗中被认为无效。研究表明，肝转移灶的进展而非原发肿瘤或其他器官的转移灶决定生存率。
我们报告一例57岁男性，经动脉化疗栓塞治疗不可切除的葡萄膜黑色素瘤肝转移灶，使用伊立替康洗脱微球。治疗分别在诊断转移性疾病后41个月和45个月实现了长期无进展生存和总生存。患者未经历该治疗的任何严重副作用。随访CT显示根据mRECIST标准疾病稳定，根据CHOI标准部分缓解。
使用负载伊立替康的药物洗脱微球经动脉化疗栓塞可能是治疗不可切除的葡萄膜黑色素瘤肝转移灶的有效方法。
